299 related articles for article (PubMed ID: 33298918)
1. Primary effusion lymphoma enhancer connectome links super-enhancers to dependency factors.
Wang C; Zhang L; Ke L; Ding W; Jiang S; Li D; Narita Y; Hou I; Liang J; Li S; Xiao H; Gottwein E; Kaye KM; Teng M; Zhao B
Nat Commun; 2020 Dec; 11(1):6318. PubMed ID: 33298918
[TBL] [Abstract][Full Text] [Related]
2. Kaposi's Sarcoma-Associated Herpesvirus Drives a Super-Enhancer-Mediated Survival Gene Expression Program in Primary Effusion Lymphoma.
Manzano M; Günther T; Ju H; Nicholas J; Bartom ET; Grundhoff A; Gottwein E
mBio; 2020 Aug; 11(4):. PubMed ID: 32843547
[TBL] [Abstract][Full Text] [Related]
3. TAF Family Proteins and MEF2C Are Essential for Epstein-Barr Virus Super-Enhancer Activity.
Wang C; Jiang S; Zhang L; Li D; Liang J; Narita Y; Hou I; Zhong Q; Gewurz BE; Teng M; Zhao B
J Virol; 2019 Aug; 93(16):. PubMed ID: 31167905
[TBL] [Abstract][Full Text] [Related]
4. Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors.
Gopalakrishnan R; Matta H; Tolani B; Triche T; Chaudhary PM
Oncogene; 2016 Apr; 35(14):1797-810. PubMed ID: 26119939
[TBL] [Abstract][Full Text] [Related]
5. CK1α and IRF4 are essential and independent effectors of immunomodulatory drugs in primary effusion lymphoma.
Patil A; Manzano M; Gottwein E
Blood; 2018 Aug; 132(6):577-586. PubMed ID: 29954751
[TBL] [Abstract][Full Text] [Related]
6. Druggable host gene dependencies in primary effusion lymphoma.
Kuehnle N; Gottwein E
Curr Opin Virol; 2022 Oct; 56():101270. PubMed ID: 36182745
[TBL] [Abstract][Full Text] [Related]
7. Restoring PU.1 induces apoptosis and modulates viral transactivation via interferon-stimulated genes in primary effusion lymphoma.
Goto H; Kariya R; Kudo E; Okuno Y; Ueda K; Katano H; Okada S
Oncogene; 2017 Sep; 36(37):5252-5262. PubMed ID: 28481873
[TBL] [Abstract][Full Text] [Related]
8. Gene essentiality landscape and druggable oncogenic dependencies in herpesviral primary effusion lymphoma.
Manzano M; Patil A; Waldrop A; Dave SS; Behdad A; Gottwein E
Nat Commun; 2018 Aug; 9(1):3263. PubMed ID: 30111820
[TBL] [Abstract][Full Text] [Related]
9. Disruption of BRD4 at H3K27Ac-enriched enhancer region correlates with decreased c-Myc expression in Merkel cell carcinoma.
Sengupta D; Kannan A; Kern M; Moreno MA; Vural E; Stack B; Suen JY; Tackett AJ; Gao L
Epigenetics; 2015; 10(6):460-6. PubMed ID: 25941994
[TBL] [Abstract][Full Text] [Related]
10. Enhancer Connectome Nominates Target Genes of Inherited Risk Variants from Inflammatory Skin Disorders.
Jeng MY; Mumbach MR; Granja JM; Satpathy AT; Chang HY; Chang ALS
J Invest Dermatol; 2019 Mar; 139(3):605-614. PubMed ID: 30315781
[TBL] [Abstract][Full Text] [Related]
11. The hyper-activation of transcriptional enhancers in breast cancer.
Li QL; Wang DY; Ju LG; Yao J; Gao C; Lei PJ; Li LY; Zhao XL; Wu M
Clin Epigenetics; 2019 Mar; 11(1):48. PubMed ID: 30867030
[TBL] [Abstract][Full Text] [Related]
12. Detection of Enhancer-Associated Rearrangements Reveals Mechanisms of Oncogene Dysregulation in B-cell Lymphoma.
Ryan RJ; Drier Y; Whitton H; Cotton MJ; Kaur J; Issner R; Gillespie S; Epstein CB; Nardi V; Sohani AR; Hochberg EP; Bernstein BE
Cancer Discov; 2015 Oct; 5(10):1058-71. PubMed ID: 26229090
[TBL] [Abstract][Full Text] [Related]
13. Enhancer identification in mouse embryonic stem cells using integrative modeling of chromatin and genomic features.
Chen CY; Morris Q; Mitchell JA
BMC Genomics; 2012 Apr; 13():152. PubMed ID: 22537144
[TBL] [Abstract][Full Text] [Related]
14. Molecular mechanisms of activating c-MET in KSHV+ primary effusion lymphoma.
Lam BQ; Dai L; Li L; Qiao J; Lin Z; Qin Z
Oncotarget; 2017 Mar; 8(11):18373-18380. PubMed ID: 28407694
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of primary effusion lymphoma engraftment in SCID mice by morpholino oligomers against early lytic genes of Kaposi's sarcoma-associated herpesvirus.
Zhang YJ; Patel D; Nan Y; Fan S
Antivir Ther; 2011; 16(5):657-66. PubMed ID: 21817187
[TBL] [Abstract][Full Text] [Related]
16. Epstein-Barr virus nuclear antigen leader protein localizes to promoters and enhancers with cell transcription factors and EBNA2.
Portal D; Zhou H; Zhao B; Kharchenko PV; Lowry E; Wong L; Quackenbush J; Holloway D; Jiang S; Lu Y; Kieff E
Proc Natl Acad Sci U S A; 2013 Nov; 110(46):18537-42. PubMed ID: 24167291
[TBL] [Abstract][Full Text] [Related]
17. Transcriptional Dysregulation of MYC Reveals Common Enhancer-Docking Mechanism.
Schuijers J; Manteiga JC; Weintraub AS; Day DS; Zamudio AV; Hnisz D; Lee TI; Young RA
Cell Rep; 2018 Apr; 23(2):349-360. PubMed ID: 29641996
[TBL] [Abstract][Full Text] [Related]
18. Altering the Anti-inflammatory Lipoxin Microenvironment: a New Insight into Kaposi's Sarcoma-Associated Herpesvirus Pathogenesis.
Chandrasekharan JA; Huang XM; Hwang AC; Sharma-Walia N
J Virol; 2016 Dec; 90(24):11020-11031. PubMed ID: 27681120
[TBL] [Abstract][Full Text] [Related]
19. Regulatory elements in the immunoglobulin heavy chain gene 3'-enhancers induce c-myc deregulation and lymphomagenesis in murine B cells.
Wang J; Boxer LM
J Biol Chem; 2005 Apr; 280(13):12766-73. PubMed ID: 15687498
[TBL] [Abstract][Full Text] [Related]
20. A model of active transcription hubs that unifies the roles of active promoters and enhancers.
Zhu I; Song W; Ovcharenko I; Landsman D
Nucleic Acids Res; 2021 May; 49(8):4493-4505. PubMed ID: 33872375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
